Clinical trials: Antiplatelet Drug
Acute Coronary Syndrome
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
- Trial name
- NCT00619164
- Testing
- E5555
- Where
- 33 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without…
- Trial name
- NCT05162131
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 872 sites in United States, Australia and 45 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Antiplatelet Drug
Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers
This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects.
- Trial name
- NCT04404790
- Testing
- Anfibatide 5 IU/60kg, Anfibatide 5 IU/60kg +0.002 IU/kg/h, Anfibatide 5 IU/60kg +0.004 IU/kg/h
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease (PAD)
Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interests in patients with peripheral arterial disease (PAD) Secondary objectives: To…
- Trial name
- NCT00862420
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 431 people
- Sponsor
- Sanofi
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Stable Angina, Myocardial Infarction
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which…
- Trial name
- CLEAN (NCT00821834)
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Coronary Artery Disease, Percutaneous Coronary Intervention
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention （PCI） will…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
- Trial name
- NCT03599284
- Testing
- Vicagrel 5mg, Vicagrel 6mg, Vicagrel 7.5mg
- Where
- 27 sites in China
- Volunteers
- 279 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs
Study of AggreGuide A-100 (ADP) Assay
Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
- Trial name
- NCT03111420
- Testing
- P2Y12 inhibitor, Platelet function test
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Aggredyne, Inc.
Platelet Aggregation Inhibitors, NSTEACS
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation…
- Trial name
- NCT00325390
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 800 people
- Sponsor
- Sanofi
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
Acute Coronary Syndrome, Stroke
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008
This is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. It is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts.
- Trial name
- NCT04770194
- Testing
- SP-8008 Prototype Capsule A, SP-8008 Prototype Capsule B
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.